Full Press Release Details
Immutep to Collaborate with LabCorp to Develop Oncology Services and Products
SYDNEY, AUSTRALIA 29th October, 2020 Immutep Limited (ASX: IMM;
NASDAQ: IMMP), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, is pleased to announce that it has entered into a Licence and Collaboration Agreement with Laboratory Corporation of America
Holdings, known as LabCorp (NYSE: LH) that will support the development of immuno-oncology products or services.
Over the years, Immutep has
generated a significant amount of know-how in immuno-oncology, specifically in terms of LAG-3 , said Marc Voigt, CEO of Immutep.
Under the terms of the Agreement, Immutep is eligible to receive an upfront fee of US$125,000 and potential further commercial milestones and service
payments. The milestone payments, which consist of up to three payments, are tied to the commercialisation of new drugs or new indications of existing drugs that requires use of an immuno-oncology diagnostic being developed by LabCorp.
The Agreement will continue until such time as the licensed technology and associated intellectual property have been exhausted and are in the public domain,
or until terminated by either party.
The collaboration with LabCorp is unrelated to any of Immutep s own
in-house pharmaceutical development programs in cancer or autoimmune disease. Significantly, it enables Immutep to enter the immuno-oncology diagnostics field.
Immutep is a globally active biotechnology
company that is a leader in the development of LAG-3 related immunotherapeutic products for the treatment of cancer and autoimmune disease. Immutep is dedicated to leveraging its technology and expertise to
bring innovative treatment options to market for patients and to maximize value to shareholders. Immutep is listed on the Australian Securities Exchange (IMM) and on the NASDAQ (IMMP) in the United States.
Immutep s current lead product candidate is eftilagimod alpha ( efti or IMP321 ), a soluble
LAG-3 protein (LAG-3Ig) based on the LAG-3 immune control mechanism. This mechanism plays a vital role in the regulation of the T
cell immune response. Efti is currently being evaluated in combination with chemotherapy for the treatment of metastatic breast cancer in a Phase IIb clinical trial termed AIPAC (clinicaltrials.gov identifier NCT02614833); a Phase II clinical trial
being conducted in collaboration with Merck & Co., Inc., Kenilworth, NJ, USA (known as MSD outside the United States and Canada) referred to as TACTI-002 to evaluate a combination of efti
with KEYTRUDA (pembrolizumab) in several different solid tumours (clinicaltrials.gov identifier NCT03625323); a Phase I clinical trial being conducted in collaboration with Merck KGaA,
Darmstadt, Germany and Pfizer Inc. referred to as INSIGHT-004 to evaluate a combination of efti with avelumab (clinicaltrials.gov identifier NCT03252938); and a Phase I combination therapy trial in metastatic
melanoma termed TACTI-mel (clinicaltrials.gov identifier NCT02676869).
Level 12, 95 Pitt Street, Sydney NSW 2000
Additional LAG-3 products, including antibodies, for immune response
modulation in autoimmunity and cancer are being developed by Immutep s large pharmaceutical partners. Immutep is also developing an agonist of LAG-3 (IMP761) for autoimmune disease.
Further information can be found on the Company s website www.immutep.com or by contacting:
Australian Investors/Media:
+61 (0)406 759 268; cstrong@citadelmagnus.com
Tim McCarthy, LifeSci Advisors
+1 (212) 915.2564; tim@lifesciadvisors.com
announcement was authorised for release by the Board of Immutep Limited.
Level 12, 95 Pitt Street, Sydney NSW 2000